Dergiler / European Journal of Breast Health / 2019 / Cilt: 15 - Sayı: 4

Prognostic Importance of Ki-67 in Breast Cancer and Its Relationship with Other Prognostic Factors

Sayfa
256–261
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Th signifiant correlation was seen between Ki-67 and tumour grading (p=

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Th clinical feature of breast cancer is very heterogeneous because of the variable prognostic factors impact its behaviour.
📊
Temel Bulgular & Veri:Th aim ofstudy is to fid the prognostic importance of Ki-67 and to analyse the correlation between Ki-67 index and the other conventional prognostic factorsin breast cancer patients.Materials and Methods: Between 2010 and 2017, patients with invasive ductal carcinoma who received radiotherapy after surgery were included in study.
💡
Sonuç & Katkı:Th signifiant correlation was seen between Ki-67 and tumour grading (p=
🔬Tür:Araştırma Makalesi
📍Kapsam:2010 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Th clinical feature of breast cancer is very heterogeneous because of the variable prognostic factors impact its behaviour. Th aim ofstudy is to fid the prognostic importance of Ki-67 and to analyse the correlation between Ki-67 index and the other conventional prognostic factorsin breast cancer patients.Materials and Methods: Between 2010 and 2017, patients with invasive ductal carcinoma who received radiotherapy after surgery were included in study. A single pathologist re-defied of all cases retrospectively. Ki-67 were established three categories based on Ki-67 levels: low (25%).Results: A total of 258 patients were included. 46 of 258 (18%) patients were in low, 82 of 258 (32%) patients were in intermediate and 130 of258 (50%) patients were in high Ki-67 group. Thre were no correlations between menopausal status, age, and Ki-67 level. Low-pT stages tended tohave low Ki-67 expression (p=0.07). Low-pN stages correlated with low Ki-67 values (p=0.007). Patients with ECE (+) were prone to have higherKi-67 values (p=0.02). Th signifiant correlation was seen between Ki-67 and tumour grading (p=

🔖

Bu Makaleye Atıf Yap

YAVUZ, B. B., AKTAN, M., UYAR, M., KARAAĞAÇ, M., KANYILMAZ, G., FINDIK, S. (2022). Prognostic Importance of Ki-67 in Breast Cancer and Its Relationship with Other Prognostic Factors. European Journal of Breast Health, Cilt: 15 - Sayı: 4, 256–261. https://ajindex.com/articles/510791

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Ferlay J, Soerjomataram I, Erwik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1.0. Available from: URL: https://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-AndPrevalence-Worldwide-In-2012-V1.0-2012. (cited 2018 June 27)
  2. Koseoglu RD, Markoc F, Muslehiddinoglu A, Ileri AB, Deresoy FA, Etikan I. HER-2/Neu and Hormon Receptor Analysis in Breast Carcinomas and Thir Association with Clinicopathologic Parameters. Eur J Breast Health 2019; 15: 43-50. [CrossRef] 3. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikof J, Bernstein L, Enger SM, Press MF. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev 2012; 21: 1848-1855. [CrossRef] 4. Kanyilmaz G, Onder H, Aktan M, Koc M, Bora H, Karahacioglu E, Erkal SK, Yirmibesoglu Erkal E. Prognostic Importance of Ki-67 Labelling Index in Grade II Glial Tumors. Turk J Oncol 2018; 33: 48-53. [CrossRef] 5. Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology 2017; 49: 166-171. [CrossRef] 6. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thrlimann B, Senn H. Tailoring therapies improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Thrapy of Early Breast Cancer 2015. Ann Oncol 2015; 26: 1533-1546. [CrossRef] 7. Tan AC, Li BT, Nahar K, Danieletto S, Fong ES, Currer T, Parasyn A, Middleton P, Wong H, Smart D, Rutovitz JJ, McCloud P, Hughes TM, Marx GM. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer. Asia Pas J Clin Oncol 2018; 14: 161-166. [CrossRef] 8. Wiesner FG, Magener A, Fasching PA, Wesse J, Bani MR, Rauh C, Jud S, Schrauder M, Loehberg CR, Beckmann MW, Hartmann A, Lux MP. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast 2009; 18: 135-141. [CrossRef] 9. Liu S, Edgerton SM, Moore 2nd DH, Thr AD. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 2001; 7: 1716-1723
  3. Spyratos F, Ferrero-Poüs M, Trassard M, Hacène K, Phillips E, Tubiana Hulin M, Le Doussal V. Correlation between MIB-1 and other proliferation markers: clinical implication and other proliferati